EFMH
IMVT icon

E Fund Management (HK)’s Immunovant IMVT Stock Holding History

E Fund Management (HK)’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.7K Buy
771
+230
+43% +$7.01K 0.01% 238
2026
Q1 		$13.4K Buy
+541
New +$14K 0.01% 294

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

E Fund Management (HK)'s IMVT Position: Q2 2026 in Review

E Fund Management (HK) increased its Immunovant (IMVT) stake by 43% in Q2 2026, buying an estimated $7.01K and bringing the position to 771 shares worth $29.7K. The position accounts for 0.01% of the portfolio, ranked #238.

E Fund Management (HK) first reported a position in IMVT in Q1 2026 and has held it in 2 quarters since. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • E Fund Management (HK) held 771 shares of Immunovant worth $29.7K as of Q2 2026.
  • E Fund Management (HK) bought 230 Immunovant shares in Q2 2026, an estimated $7.01K.
  • Immunovant made up 0.01% of E Fund Management (HK)'s portfolio in Q2 2026, its #238 holding.
  • E Fund Management (HK) first reported a position in Immunovant in Q1 2026 and has held it in 2 quarters since.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on E Fund Management (HK)'s 13F filing for Q2 2026, filed 22 Jul 2026.